3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
7
Phase 1
4
Phase NA
2
Phase 3
2
Phase 1/2
2
Phase 2/3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Conditions
Stomach Neoplasms
5
Rectal Neoplasms
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Ovarian Neoplasms
3
Neoplasms
3
Carcinoma, Hepatocellular
3
Breast Neoplasms
3
Uterine Cervical Neoplasms
2
Small Cell Lung Carcinoma
2
Sarcoma
2
Pancreatic Neoplasms
2
Melanoma
2
Lung Neoplasms
2
Esophageal Squamous Cell Carcinoma
2
Colorectal Neoplasms
2
Sarcoma, Ewing
1
SCLC
1
Retinoblastoma
1
Osteosarcoma
1
Oligometastatic Disease
1
Neoplasms, Germ Cell and Embryonal
1
Nasopharyngeal Carcinoma
1
NSCLC
1
Mouth Neoplasms
1
Lymphoma, Follicular
1
Lymphoma
1
Locally Advanced Resectable Rectal Cancer
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Glioblastoma
1
Interventions
Cyclophosphamide
10
Etoposide
6
Doxorubicin
6
Cytarabine
6
Prednisone
5
Vincristine
4
Trimethoprim, Sulfamethoxazole Drug Combination
4
Methotrexate
4
gamma-Globulins
3
Rituximab
3
Radiotherapy
3
Filgrastim
3
Ciprofloxacin
3
pegaspargase
2
nelarabine
2
etoposide phosphate
2
calaspargase pegol
2
Triptorelin Pamoate
2
Thioguanine
2
Prednisolone
2
Methylprednisolone
2
Mercaptopurine
2
Melphalan
2
Magnetic Resonance Spectroscopy
2
Immunoglobulins, Intravenous
2
Dexamethasone
2
Daunorubicin
2
Cyclosporine
2
Calcium Dobesilate
2
Bortezomib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Lymphoma
×
Drug Therapy
×
Clear all
NCT02856048
2019-12-17
PRESOV
Assistance Publique - Hôpitaux de Paris
Phase 2/3
Unknown
11 enrolled